COMPASS

Cardiovascular OutcoMes for People using Anticoagulation StrategieS (2013,
ongoing)

Condition

Prevention of heart attacks, stroke or cardiovascular death in patients with coronary or peripheral artery disease

Close this section

Objective

To evaluate whether treatment with rivaroxaban and ASA or rivaroxaban alone is better than ASA alone in prevention of major cardiac events in patients with CAD or PAD

Close this section

Trial design

Randomized placebo-controlled phase III study, event driven, expected duration 3–4 years

Active treatment:

  • Stratum 1: rivaroxaban 2.5 mg p.o. twice daily plus ASA 100 mg once daily
  • Stratum 2: rivaroxaban 5 mg p.o twice daily plus ASA placebo

Control treatment: ASA 100 mg once daily plus rivaroxaban placebo

Close this section

Endpoints

Primary efficacy endpoint: composite of cardiovascular death, myocardial infarction and stroke
Primary safety endpoint: major bleeding
Secondary outcome measures: composite of myocardial infarction, stroke, cardiovascular death, venous thromboembolism and cardiovascular hospitalization, all-cause mortality

Close this section

Trial participants

~20,000 patients ≥18 years with documented atherosclerosis related to CAD or PAD plus one of the following inclusion criteria:

  • age ≥65 years
  • age <65 years plus documented atherosclerosis in at least two vascular
    beds or at least 2 additional risk factors

Close this section

Reference

ClinicalTrials.gov (NCT01776424)

Close this section

Corresponding author

Salim Yusuf, MD, Health Research Institute (PHRI), McMaster University, 237 Barton Street East, Hamilton, ON L8L 2X2, Canada, yusufs@mcmaster.ca

Close this section

Back To List

Recommend pageBack to top